ONX 0912

ONX 0912

CAT N°: 16269
Price:

From 92.00 78.20

ONX 0912 is an orally bioavailable proteasome inhibitor.{28242} It potently targets the chymotrypsin-like activity of the 20S proteasome subunits ?5 and LMP7 (IC50s = 36 and 82 nM, respectively).{28242} ONX 0912 inhibits the growth of multiple myeloma cells at nanomolar concentrations while not decreasing the viability of normal peripheral blood mononuclear cells at 1 µM.{28245} It blocks the growth of xenografted human multiple myeloma cells in mice when given orally.{28245} ONX 0912 has potential applications in certain types of cancer as well as other diseases that require proteasome activity.{28240,28241,28243,28244}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide
  • Correlated keywords
    • 1227167-?05-?6 1604802-58-5 ONX0912 orally bioavailable inhibitors CT-L CTL activity 20S proteasome ?5/LMP7 ?5 LMP7 PR047 ubiquitin cancer biochemicals inhibit chymotrypsin multiple myeloma MM
  • Product Overview:
    ONX 0912 is an orally bioavailable proteasome inhibitor.{28242} It potently targets the chymotrypsin-like activity of the 20S proteasome subunits ?5 and LMP7 (IC50s = 36 and 82 nM, respectively).{28242} ONX 0912 inhibits the growth of multiple myeloma cells at nanomolar concentrations while not decreasing the viability of normal peripheral blood mononuclear cells at 1 µM.{28245} It blocks the growth of xenografted human multiple myeloma cells in mice when given orally.{28245} ONX 0912 has potential applications in certain types of cancer as well as other diseases that require proteasome activity.{28240,28241,28243,28244}

We also advise you